MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Pneumonia, Pneumococcal
Arsanis Pharmaceuticals (ASNS)
Organization & Developments: Arsanis
Parents
Arsanis Pharmaceuticals (ASNS)
Children
2011: Secretive Biotech Arsanis Raises $9.6M (2011)
2017: Arsanis Pharmaceuticals: A Revolutionary Approach To Infectious Pathogens - Arsanis (Pending:ASNS)
2018: Arsanis to discontinue Phase 2 trial of pneumonia treatment_seekingalpha.com
Dedicated to the development of anti-infective monoclonal antibody therapeutics
Occur in Immune Compromised Patients
Or Are Associated with High Mortality in Spite of Low Rates of Antibiotic Resistance
Proceeds from the initial financing will be used to advance several programs in the anti-microbial infectious disease area.
The Company’s major focus is on life threatening infections that: are caused by antibiotic resistant pathogens
Jumps
*Key People: Arsanis
Finance & Acquisitions: Arsanis